A Bold Panoramic Grasp of Tardive Dyskinesia

Download All

Gain expert insights on tardive dyskinesia. Activity topics range from screening and diagnosis to management in the face of psychiatric and other comorbidities.

person default
Leslie
person default
Jacob Ballon, MD, MPH
Stanley N. Caroff, MD
Leslie Citrome, MD, MPH
Christoph U. Correll, MD
Robert O. Cotes, MD
Charles DeBattista, DMH, MD
Amber Hoberg, PMHNP
Stuart Isaacson, MD
John M. Kane, MD
Sneha Mantri, MD, MS
Greg W. Mattingly, MD
Joseph P. McEvoy, MD
Jonathan M. Meyer, MD
Rajesh Pahwa, MD
person default
Diana O. Perkins, MD, MPH
person default
Martha Sajatovic, MD
Stephen R. Saklad, PharmD, BCPP
person default
Jeremy A. Schreiber, MSN, APRN, PMHNP-BC
person default
Rajiv Tandon, MD

Managing TD: An Overview

This case example introduces a patient with a history of untreated, irregular, uncontrolled movements using the most up-to-date evidence for identification and ongoing management to optimize outcomes.

person default Jeremy A. Schreiber, MSN, APRN, PMHNP-BC Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: 0.75 AAPA Category 1 CME credits Psychologists: 0.75 APA CE Credits Social Workers: 0.75 ACE CE Credits Released: December 8, 2022 Expired: No longer available for credit

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.

Robert O. Cotes, MD Jonathan M. Meyer, MD Released: October 28, 2022

Tardive Dyskinesia Etiology

Listen to this interprofessional discussion of the various risk factors for tardive dyskinesia—including those beyond antipsychotic use—and how the etiology of the disease might impact treatment approach.

Christoph U. Correll, MD John M. Kane, MD Released: December 29, 2022

How Can We Screen for and Identify Tardive Dyskinesia?

Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.

Greg W. Mattingly, MD Jonathan M. Meyer, MD Released: July 13, 2022

It can be challenging to differentially diagnose drug-induced movement disorders. In particular, tardive dyskinesia (TD) is often confused with drug-induced parkinsonism (DIP). Although both are associated with dopamine blockade and antipsychotic medications, treatment approaches for the 2 differ significantly—making accurate diagnosis a major importance. In this commentary, Stuart Isaacson, MD, discusses how to differentiate between TD and DIP to ensure the best treatment outcome.

Stuart Isaacson, MD Released: December 21, 2022

Living With TD

A patient with tardive dyskinesia tells her story about the process of receiving an accurate diagnosis and how the disorder has affected her life.

person default Leslie Released: October 13, 2022

Listen to Leslie, a patient with TD for the past 10 years, describe her experience with the disease from diagnosis to current impact on her daily life.

person default Leslie Joseph P. McEvoy, MD Released: September 28, 2022

Avoiding Common Mistakes in Tardive Dyskinesia Management

Tardive dyskinesia can be tricky to identify and manage. Here, Greg Mattingly, MD, describes the common mistakes he observes in TD care and how to avoid them in your clinical practice.

Greg W. Mattingly, MD Released: July 13, 2022

TD Management Options

A series of case challenges demonstrating tardive dyskinesia diagnosis and management in 3 unique patients.

Stanley N. Caroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: December 30, 2022 Expired: No longer available for credit

Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management.

person default Diana O. Perkins, MD, MPH person default Rajiv Tandon, MD Released: October 17, 2022

Following recent live conferences, expert faculty answer your most asked questions on tardive dyskinesia screening and management.

Leslie Citrome, MD, MPH Charles DeBattista, DMH, MD Stuart Isaacson, MD Greg W. Mattingly, MD Jonathan M. Meyer, MD Rajesh Pahwa, MD Released: December 6, 2022

TD Progression

Read this interactive case study by Sneha Mantri, MD, MS, demonstrating comprehensive and individualized care for a patient with bipolar disorder and recently developed tardive dyskinesia.

Sneha Mantri, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: November 29, 2022 Expired: No longer available for credit

VMAT2 Inhibitors TD

The risk of tardive dyskinesia has been a barrier to treating patients with antipsychotics. Now, however, there are treatment options available to treat tardive dyskinesia. Stephen R. Saklad, PharmD, BCPP, discusses the VMAT2 inhibitors and how they have revolutionized how we think about tardive dyskinesia.

Stephen R. Saklad, PharmD, BCPP Released: November 28, 2022

Using AIMS in TD

Tardive dyskinesia exists in many patients—likely more than we are aware of. To connect these patients to treatment, we need to accurately identify the movement disorder. The Abnormal Involuntary Movement Scale is imperative to diagnosing and following patients with tardive dyskinesia in clinical practice.

Leslie Citrome, MD, MPH Released: August 16, 2022

The population of older patients with psychiatric conditions is increasing and, with it, the prevalence of tardive dyskinesia. Read on to gain a geropsychiatrist’s insights on preventing and managing TD in this vulnerable patient population.

person default Martha Sajatovic, MD Released: October 11, 2022

Initiating TD Management

Read this interactive case study by Jacob Ballon, MD, MPH, demonstrating the first steps of TD diagnosis and management in patients with primary mood disorders.

person default Jacob Ballon, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credits Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: September 30, 2022 Expired: No longer available for credit

Research Review

In this video roundtable activity, Christoph U. Correll, MD; Leslie Citrome, MD, MPH; and Amber Hoberg, PMHNP, discuss recently published articles of interest in tardive dyskinesia care.

Leslie Citrome, MD, MPH Christoph U. Correll, MD Amber Hoberg, PMHNP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Physician Assistants: maximum of 1.0 hour of AAPA Category 1 credit Released: October 19, 2022 Expired: No longer available for credit

Slides summarizing recent research in tardive dyskinesia.

Leslie Citrome, MD, MPH Christoph U. Correll, MD Amber Hoberg, PMHNP Released: October 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings